Alector (ALEC) news
Recent news
Alector Inc: Morgan Stanley raises target price to $3.00 from $2.00
Morgan Stanley has raised its price target for Alector Inc (NASDAQ: ALEC) to $3.00 from $2.00, maintaining an "Underweight" rating on the stock. The adjustment follows recent developments, including the company’s strategic shift to focus on its Alector Brain Carrier (ABC) platform for…
AInvest Wire · 6d agoAlector shares jump 21.5% to $2.19 after Roche inks up to $1.27 bln licensing agreement for co's Parkinson's therapy
Alector Inc. (ALTR) shares rose 21.5% to $2.19 on Thursday following the announcement of a licensing agreement with Roche Holding AG for the development of Alector’s experimental Parkinson’s disease therapy, AL001 [1]. Under the terms of the deal, Roche will pay Alector up to $1.27 billion,…
AInvest Wire · 7d agoAlector shares jump 77.4% to $3.21 premarket after Roche inks up to $1.27 bln licensing agreement for co's Parkinson's therapy
Alector Inc. (ALEC) shares surged 77.4% to $3.21 in premarket trading following the announcement of a licensing agreement with Roche for its Parkinson’s disease therapy. The deal, valued up to $1.27 billion, includes upfront payments and potential milestone-based incentives, reflecting strong…
AInvest Wire · 7d agoAlector eligible for up to $1.17B in milestone payments
AInvest Wire · 7d agoAlector enters global license pact with Genentech
AInvest Wire · 7d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.